{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:27Z","timestamp":1787027067864,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074348, 82274491"],"award-info":[{"award-number":["82074348, 82274491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023LZL009"],"award-info":[{"award-number":["ZR2023LZL009"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hematological diseases, as a category of malignant tumors originating from the hematopoietic system, have long relied on treatments such as chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. However, challenges remain in managing locally progressive lesions, relapsed\/refractory lesions, and involvement of special anatomical sites, especially in infirmities. Ablation technology, as a minimally invasive local treatment method, directly destroys lesion tissues through physical energy and has been widely used in the field of solid tumors. In recent years, with advancements in image-guided technology and the presence of unmet clinical needs in the local treatment of hematological diseases, studies have begun to explore the application of ablation technology in hematological diseases. We retrospectively analyzed 4 frail hematological malignancies cases to discuss the application significance and indications of local ablation therapy in hematological diseases of frail patients, aiming to provide references for clinical practice.Case 1 and Case 2 involved patients with relapsed\/refractory multiple myeloma. Both patients had extramedullary lesions in the left maxillary region and the left tibial anterior area, and were unable to tolerate intensive treatment. Case 3 was diagnosed with diffuse large B-cell lymphoma (DLBCL) combined with large extramedullary lesion masses. Case 4 was diagnosed with DLBCL combined with synovial sarcoma. Case 3 and 4 patients were over 80 years old. The four patients were treated with a combination of local ablation and low-dose systemic chemotherapy. After the treatment, all four patients achieved varying degrees of remission, improvement in local compression symptoms, and enhancement of quality of life, with no obvious side effects. Our study demonstrated for the first time the good safety and efficacy of ablation combined with chemotherapy for frail patients, and also indicated that ablation can be used as a new treatment strategy for elderly frail B-cell malignancies patients with local extramedullary lesions who cannot tolerate intense systemic treatment, or for those B-cell malignancies with multiple relapses.<\/jats:p>","DOI":"10.3389\/fonc.2025.1723537","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:31Z","timestamp":1762751911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Ablation as novel x therapy in the regimen for frail hematological malignancies with extramedullary lesion"],"prefix":"10.3389","volume":"15","author":[{"given":"Muyun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Transl Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","article-title":"Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution","volume":"12","author":"Jim\u00e9nez-Segura","year":"2022","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015072","article-title":"Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review","volume":"9","author":"Wang","year":"2025","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1872069","article-title":"The presence of a bulky mediastinal mass of 7cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET\/CT","volume":"62","author":"Lopez-Alonso","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I\u2013II indolent non-hodgkin\u2019s lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e70207","DOI":"10.1002\/hem3.70207","article-title":"Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"9","author":"Thieblemont","year":"2025","journal-title":"Hemasphere"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019543","article-title":"Decoding the molecular heterogeneity of pediatric monomorphic post\u2013solid organ transplant lymphoproliferative disorders","volume":"142","author":"Salmer\u00f3n-Villalobos","year":"2023","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24346","article-title":"Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival","volume":"91","author":"Rosenberg","year":"2016","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients \u2013 BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-221369","article-title":"Ablation for lung cancer: hot or cold intervention","volume":"79","author":"Shah","year":"2024","journal-title":"Thorax"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.20386","article-title":"Percutaneous microwave ablation and cementoplasty: clinical utility in the treatment of painful extraspinal osseous metastatic disease and myeloma","volume":"212","author":"Deib","year":"2019","journal-title":"Am J roentgenol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.11405\/nisshoshi.103.655","article-title":"Nihon shokakibyo gakkai zasshi","volume":"103","author":"Hamada","year":"2006","journal-title":"Japanese J gastro-enterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2063","article-title":"Non-transplantable recurrence after percutaneous thermal ablation of \u22643-cm HCC: Predictors and implications for treatment allocation","volume":"6","author":"Gozzo","year":"2022","journal-title":"Hepatol Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave tumor ablation: mechanism of action, clinical results and devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bjh.13799","article-title":"Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study","volume":"172","author":"Muchtar","year":"2016","journal-title":"Br J Haematology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1970218","article-title":"Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"53","author":"Zhang","year":"2021","journal-title":"Ann Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28557","DOI":"10.1038\/s41598-024-79537-2","article-title":"Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease","volume":"14","author":"Yin","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152672","article-title":"Phase IB study of oral selinexor in combination with rituximab and platinum chemotherapy in patients with relapsed\/refractory B-cell lymphoma\u2014Final analysis","volume":"16","author":"Maerevoet","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14208","DOI":"10.1111\/ajco.14208","article-title":"A multicenter real-world study of outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with a polatuzumab vedotin-based regimen in a compassionate use program in Malaysia","volume":"21","author":"Wahid","year":"2025","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27151","article-title":"R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study","volume":"99","author":"Al-Sarayfi","year":"2024","journal-title":"Am J Hematology"},{"key":"B29","article-title":"Treating newly diagnosed Diffuse Large B-cell Lymphoma in the elderly patient with R-mini-CHOP: A single centre analytical retrospective observational study","volume":"80","author":"Lim","year":"2025","journal-title":"The Medical journal of Malaysia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11864-018-0565-6","article-title":"Treating diffuse large B cell lymphoma in the very old or frail patients","volume":"19","author":"Kumar","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_623_17","article-title":"Proptosis and hemiplegia as an initial manifestation of multiple myeloma","volume":"64","author":"Tahiliani","year":"2018","journal-title":"J Postgrad Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/168785","article-title":"Recurrent plasmacytomas after allografting in a patient with multiple myeloma","volume":"2012","author":"Stawis","year":"2012","journal-title":"Case Rep Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.2597","article-title":"Radiotherapy vs surgery for survival and locoregional control of head and neck extramedullary plasmacytoma: A systematic review and meta-analysis","volume":"150","author":"Vasudevan","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e86350","DOI":"10.7759\/cureus.86350","article-title":"Radiotherapy for orbital myeloid sarcoma as extramedullary relapse in a pediatric acute myeloid leukemia patient post-haploidentical bone marrow transplantation","volume":"17","author":"Ghafouri","year":"2025","journal-title":"Cureus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2019-0045","article-title":"A multi-institutional analysis of diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiotherapy and the impact of cell-of-origin on outcomes","volume":"53","author":"Rajasooriyar","year":"2019","journal-title":"Radiol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70078-0","article-title":"Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203645","article-title":"Impact of consolidation radiotherapy in bulky diffuse large B cell lymphoma by PET based response assessment","volume":"144","author":"Nair","year":"2024","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e904","DOI":"10.1097\/HS9.0000000000000904","article-title":"Radiation and dose-densification of R-CHOP in aggressive B-cell lymphoma with intermediate prognosis: the UNFOLDER study","volume":"7","author":"Thurner","year":"2023","journal-title":"Hemasphere"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2024.06.003","article-title":"Radiation therapy dose response in bulky relapsed\/refractory large B-cell lymphoma","volume":"14","author":"Baron","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5680","article-title":"Efficacy and safety of percutaneous microwave ablation and cementoplasty in the treatment of painful spinal metastases and myeloma","volume":"39","author":"Khan","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1008828","article-title":"Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell Malignancies with bulky disease","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/0300060521999539","article-title":"A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review","volume":"49","author":"Xu","year":"2021","journal-title":"J Int Med Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802524837","article-title":"Radiofrequency ablation of hepatic Hodgkin lymphoma","volume":"50","author":"Rusconi","year":"2009","journal-title":"Leukemia Lymphoma"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2131","article-title":"Radiofrequency ablation of lymphoma","volume":"107","author":"Sudheendra","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.03.048","article-title":"Successful percutaneous treatment of bone tumors using microwave ablation in combination with Zoledronic acid infused PMMA cementoplasty","volume":"76","author":"Luna","year":"2020","journal-title":"J Clin Neurosci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1723537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:35Z","timestamp":1762751915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1723537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1723537"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1723537","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1723537"}}